LAB (Standard BioTools) Non Operating Income: $-40.25 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LAB Standard BioTools Inc LAB
33 GF Score
Price $0.65
GF Value $0.71
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Standard BioTools Non Operating Income?

Standard BioTools LAB -3.41% 33 Non Operating Income is $-40.25 Mil as of Jun. 2026. GuruFocus rates LAB with a GF Score™ of 33/100 and a GF Value™ of $0.71 (Fairly Valued). The stock has 5 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Standard BioTools's Non Operating Income for the three months ended in Jun. 2026 was $-18.22 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-40.25 Mil.

Standard BioTools Non Operating Income Related Terms

Standard BioTools Non Operating Income Historical Data

* Premium members only.

The historical data trend for Standard BioTools's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Standard BioTools Non Operating Income Chart

Standard BioTools Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.62 -88.21 -12.17 -20.27 -12.55

Standard BioTools Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.97 -11.56 -1.76 -8.71 -18.22
LAB
33GF Score
Standard BioTools Inc LAB
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Standard BioTools Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-40.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-40.25 Mil mean?
Standard BioTools (LAB) has a Non Operating Income of $-40.25 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Standard BioTools and its competitors.
Is Standard BioTools' Non Operating Income too high?
Standard BioTools' current Non Operating Income is $-40.25 Mil. Overall, Standard BioTools has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Non Operating Income compare to CV and ELMD?
Standard BioTools' Non Operating Income of $-40.25 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Medical Devices & Instruments company?
A good Non Operating Income depends on the Medical Devices & Instruments industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Standard BioTools and its competitors. Standard BioTools's current Non Operating Income is $-40.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (LAB) is currently considered Fairly Valued. The stock's GF Value™ is $0.71, compared to a current price of $0.65 — trading 8.6% below its estimated fair value. The current Non Operating Income is $-40.25 Mil. Standard BioTools' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Standard BioTools (LAB), the current Non Operating Income is $-40.25 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Standard BioTools (LAB) Overvalued in 2026?

Based on GuruFocus' analysis, Standard BioTools stock appears to be undervalued. The current stock price of $0.65 is trading 8.6% below its estimated GF Value™ of $0.71. GuruFocus considers Standard BioTools to be Fairly Valued.

Key valuation signals for LAB:

  • Non Operating Income: $-40.25 Mil
  • GF Value™: $0.71 vs. price of $0.65 (8.6% below fair value)
  • GF Score™: 33/100 with 5 warning signs

No single metric tells the full story. See the LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Standard BioTools Business Description

Other Exchanges FLB:Germany
Address 50 Milk Street, 10th Floor, Boston, MA, USA, 02109
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
33GF Score

Get the complete analysis for LAB

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price
$0.71
GF Value